Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug961 | Cognitive testing Wiki | 0.71 |
| drug2247 | MRI (heart, brain, lungs, kidney) Wiki | 0.71 |
| drug4564 | mMRC (Modified Medical Research Council) Dyspnea Scale Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3692 | St. George's Respiratory Questionnaire (SGRQ) Wiki | 0.71 |
| drug4712 | risk factors Wiki | 0.71 |
| drug240 | Airwave Oscillometry Wiki | 0.71 |
| drug3640 | Six-minute walk test (6MWT) Wiki | 0.71 |
| drug2674 | Olfaction testing Wiki | 0.71 |
| drug4175 | V/Q SPECT-CT Wiki | 0.71 |
| drug4284 | Walk Test Wiki | 0.71 |
| drug619 | Bloodwork Wiki | 0.71 |
| drug3011 | Plethysmography & DLCO Wiki | 0.71 |
| drug1775 | Hydroxychloroquine Wiki | 0.07 |
| drug2916 | Placebo Wiki | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016638 | Critical Illness NIH | 0.09 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
While many people with COVID-19 suffer from respiratory disease, there is growing evidence that the virus also affects other organs. The purpose of this study is to better understand the effects of COVID-19 on the lungs and other organs. The study investigators have developed new techniques in Magnetic Resonance Imaging (MRI) to scan the lungs, heart, brain and liver. The study investigators hope to learn more about how the virus causes inflammation in these organs and how this inflammation changes over time as people recover from COVID-19 illness. The study aims to enroll 228 people in Alberta. Participants will undergo one or more MRI scans and have blood testing at one or more time points to assess for inflammation, kidney function, liver function and possible heart injury. Participants will also undergo testing to assess sense of smell, cognition (thinking and memory), spirometry (breathing test for lung function) and and exercise tolerance (walk test). The study investigators hope this study will help us learn more about the long-term risks of COVID-19 disease.
Description: Myocardial T1 is a surrogate marker of myocardial edema and the most sensitive MRI measure of acute myocarditis. We will show that myocardial T1 at baseline is significantly higher than myocardial T1 at 12 weeks follow-up. At 12 weeks, we will also compare native myocardial T1 in patients with baseline elevated troponin to those with baseline normal troponin as well as healthy controls
Measure: Native myocardial T1 relaxation time Time: 12 weeks post COVID-19 diagnosisDescription: Similar within group and between group comparisons of MRI derived lung water content, liver water content, and the presence of brain inflammation on FLAIR imaging
Measure: FLAIR imaging Time: 12 weeks post COVID-19 diagnosisDescription: Compare 12-week cognitive testing (NIH toolbox score) to the corresponding findings on MRI of brain, heart and lung at baseline
Measure: Compare 12-week cognitive testing to the corresponding findings on MRI of brain, heart and lung at baseline Time: 12 weeks post COVID-19 diagnosisDescription: Compare 12-week spirometry (FEV1, FVC and FEV1:FVC) to the corresponding findings on MRI of brain, heart and lung at baseline
Measure: Compare 12-week spirometry to the corresponding findings on MRI of brain, heart and lung at baseline Time: 12 weeks post COVID-19 diagnosisDescription: Compare 12-week walk test results (distance and time) to the corresponding findings on MRI of brain, heart and lung at baseline
Measure: Compare 12-week walk test results to the corresponding findings on MRI of brain, heart and lung at baseline Time: 12 weeks post COVID-19 diagnosisDescription: Compare 12-week cognitive testing in patients with normal smell and/or normal appearing brainstem on MRI to patients with no or impaired smell and/or injury to brainstem on MRI
Measure: Compare 12-week cognitive testing in patients with normal smell and/or normal appearing brainstem on MRI to patients with no or impaired smell and/or injury to brainstem on MRI Time: 12 weeks post COVID-19 diagnosisDescription: Compare MRI measures of organ dysfunction at 12-24 weeks in survivors according to severity of prior COVID-19 illness: (i) hospitalized, (ii) symptomatic, not hospitalized and (iii) asymptomatic
Measure: Compare MRI measures of organ dysfunction at 12-24 weeks in survivors according to severity of prior COVID-19 illness: (i) hospitalized, (ii) symptomatic, not hospitalized and (iii) asymptomatic Time: 12-24 weeks post COVID-19 diagnosisLittle is currently known about the immediate and long-term effect of COVID-19 on lung ventilation (delivery of air to the lungs) and lung perfusion (delivery of blood to the lungs). Some people who survive COVID-19 may have lung ventilation and/or perfusion injury that persists following COVID-19 recovery. This lung injury may be related to inflammation in the lung, breathlessness, exercise limitation and reduced quality of life. Therefore, towards the goal of understanding the effects of COVID-19 on lung health, the purpose of this study is to characterize and understand the clinical relevance of COVID-19 related lung ventilation and perfusion injury and associated inflammatory status, ≤4 weeks and 6-months following COVID-19 recovery in an asthmatic and healthy population. To do this, an asthmatic and healthy population who have, and have not, been previously diagnosed with COVID-19 will be studied.
Description: The short-term difference in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: The short-term difference in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: The short-term difference in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Short-term difference in lung ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: The long-term difference in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - healthy Time: 6-months post COVID-19 recovery (Visit 2)Description: The long-term difference in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - healthy Time: 6-months post COVID-19 recovery (Visit 2)Description: The long-term difference in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy Time: 6-months post COVID-19 recovery (Visit 2)Description: The short-term difference in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measure: Short-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: The short-term difference in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measure: Short-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: The short-term difference in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measure: Short-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: The long-term difference in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measure: Long-term difference in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic Time: 6-months post COVID-19 recovery (Visit 2)Description: The long-term difference in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measure: Long-term difference in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic Time: 6-months post COVID-19 recovery (Visit 2)Description: The long-term difference in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants
Measure: Long-term difference in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic Time: 6-months post COVID-19 recovery (Visit 2)Description: Difference in the 6-month change in lung ventilation between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - healthy Time: 6-months post COVID-19 recovery (Visit 2)Description: Difference in the 6-month change in lung perfusion between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - healthy Time: 6-months post COVID-19 recovery (Visit 2)Description: Difference in the 6-month change in lung ventilation/perfusion mismatch between healthyCOVID-19+ and healthyCOVID-19- participants
Measure: Longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - healthy Time: 6-months post COVID-19 recovery (Visit 2)Description: Difference in the 6-month change in lung ventilation between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
Measure: Longitudinal change in ventilation defect percent assessed by ventilation SPECT-CT - asthmatic Time: 6-months post COVID-19 recovery (Visit 2)Description: Difference in the 6-month change in lung perfusion between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
Measure: Longitudinal change in perfusion defect percent assessed by perfusion SPECT-CT - asthmatic Time: 6-months post COVID-19 recovery (Visit 2)Description: Difference in the 6-month change in lung ventilation/perfusion mismatch between asthmaticCOVID-19+ and asthmaticCOVID-19- participants.
Measure: Longitudinal change in ventilation/perfusion mismatch assessed by ventilation/perfusion SPECT-CT - asthmatic Time: 6-months post COVID-19 recovery (Visit 2)Description: In COVID-19+ participants, the correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score ≤4-weeks post COVID-19 recovery (Visit 1).
Measure: Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score ≤4-weeks post COVID-19 recovery Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: In COVID-19+ participants, the correlation of lung ventilation with six-minute walk distance (6MWD) ≤4-weeks post COVID-19 recovery (Visit 1).
Measure: Correlation of lung ventilation with six-minute walk distance (6MWD) ≤4-weeks post COVID-19 recovery Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: In COVID-19+ participants, the correlation of lung ventilation with the forced expiratory volume in one second (FEV1) ≤4-weeks post COVID-19 recovery (Visit 1).
Measure: Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) ≤4-weeks post COVID-19 recovery Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: In COVID-19+ participants, the correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) ≤4-weeks post COVID-19 recovery (Visit 1).
Measure: Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) ≤4-weeks post COVID-19 recovery Time: ≤4-weeks post COVID-19 recovery (Visit 1)Description: In COVID-19+ participants, the correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score 6-months post COVID-19 recovery (Visit 2).
Measure: Correlation of lung ventilation with the St. George's Respiratory Questionnaire (SGRQ) score 6-months post COVID-19 recovery Time: 6-months post COVID-19 recovery (Visit 2)Description: In COVID-19+ participants, the correlation of lung ventilation with six-minute walk distance (6MWD) 6-months post COVID-19 recovery (Visit 2).
Measure: Correlation of lung ventilation with six-minute walk distance (6MWD) 6-months post COVID-19 recovery Time: 6-months post COVID-19 recovery (Visit 2)Description: In COVID-19+ participants, the correlation of lung ventilation with the forced expiratory volume in one second (FEV1) 6-months post COVID-19 recovery (Visit 2).
Measure: Correlation of lung ventilation with the forced expiratory volume in one second (FEV1) 6-months post COVID-19 recovery Time: 6-months post COVID-19 recovery (Visit 2)Description: In COVID-19+ participants, the correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) 6-months post COVID-19 recovery (Visit 2).
Measure: Correlation of lung ventilation with the diffusing capacity of the lung for carbon monoxide (DLCO) 6-months post COVID-19 recovery Time: 6-months post COVID-19 recovery (Visit 2)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports